{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=21", "query": { "condition": "Relapse Leukemia", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1826, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T13:48:24.164Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03318016", "title": "Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cyclophosphamide 500 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 1000 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 2000 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 3000 MG", "type": "DRUG" }, { "name": "Cyclophosphamide 4000 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2017-12-15", "completion_date": "2021-01-20", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03318016" }, { "nct_id": "NCT01131247", "title": "PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "ofatumumab + bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nevada Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-07-20", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 1, "location_summary": "PHoenix/Scottsdale, Arizona", "locations": [ { "city": "PHoenix/Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01131247" }, { "nct_id": "NCT04848064", "title": "Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Adult T-Cell Leukemia/Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "BIOLOGICAL" }, { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "John Reneau", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-05-06", "completion_date": "2027-01-30", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04848064" }, { "nct_id": "NCT02557516", "title": "Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "monalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innate Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2015-11-09", "completion_date": "2019-09-25", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02557516" }, { "nct_id": "NCT00718757", "title": "Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Hodgkin's Disease", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 4, "start_date": "2005-01", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 2, "location_summary": "San Diego, California • Memphis, Tennessee", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00718757" }, { "nct_id": "NCT02952508", "title": "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia", "Multiple Myeloma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Lymphoplasmacytic Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Central Nervous System Lymphoma" ], "interventions": [ { "name": "Iopofosine I 131 single dose", "type": "DRUG" }, { "name": "Iopofosine I 131 multiple dose", "type": "DRUG" }, { "name": "Iopofosine I 131 fractionated dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2017-07-26", "completion_date": "2027-12-22", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 29, "location_summary": "Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952508" }, { "nct_id": "NCT04278768", "title": "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Emavusertib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2020-07-06", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 12, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278768" }, { "nct_id": "NCT01130662", "title": "Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "combination therapy using decitabine and midostaurin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2010-03", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2013-03-26", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130662" }, { "nct_id": "NCT04726241", "title": "The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Juvenile Myelomonocytic Leukemia", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome Post Cytotoxic Therapy", "Myeloid Leukemia Associated With Down Syndrome" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "PedAL BCU, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 960, "start_date": "2022-04-18", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 164, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04726241" }, { "nct_id": "NCT02145403", "title": "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies", "Relapse", "Graft-Versus-Host Disease" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 53, "start_date": "2014-10", "completion_date": "2020-10-16", "has_results": true, "last_update_posted_date": "2022-01-03", "last_synced_at": "2026-11-07T13:48:24.164Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02145403" } ] }